TITLE

Biological value of melanoma inhibitory activity serum concentration in patients with primary skin melanoma

PUB. DATE
June 2008
SOURCE
Croatian Medical Journal;2008, Vol. 49 Issue 3, p451
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
33057307

 

Related Articles

  • Melanoma inhibitory activity serum marker in the follow-up of patients with melanoma. Sisu, Roxana // Maedica - a Journal of Clinical Medicine;2009, Vol. 4 Issue 1, p63 

    The article discusses the study on the diagnostic value of melanoma inhibitory activity (MIA) serum marker in patients with cutaneous melanoma. The author cites the occurrence of metastasis in 137 patients in the study with sensitivity of MIA testing of 67.6% in stage I and 65.6% in stage II...

  • Elevated MIA Serum Levels are of Relevance for Management of Metastasized Malignant Melanomas: Results of a German Multicenter Study1. Bosserhoff, Anja Katrin; Hauschild, Axel; Hein, Rüdiger; Schadendorf, Dirk; Stockfleth, Eggert; Bogenrieder, Thomas; Landthaler, Michael; Buettner, Reinhard; Stolz, Wilhelm // Journal of Investigative Dermatology;Feb2000, Vol. 114 Issue 2, p395 

    Presents a letter to the editor on dermatology of 'The Journal of Investigative Dermatology'. Relevance of elevated melanoma inhibitory activity (MIA) in managing metastasized malignant melanomas; Investigation of serum samples of melanoma patients; Correlation between MIA level and tumor load.

  • Současný výskyt pÄ›ti primárních melanomů u jednoho pacienta. Paťavová, V.; Drlík, L.; Slezáková, L.; Pock, L. // Czecho-Slovak Dermatology / Cesko-Slovenska Dermatologie;2015, Vol. 90 Issue 4, p141 

    Thee authors describe a case of a man who was simultaneously diagnosed with nodular melanoma, two superficial and two in situ melanomas. Development of multiple primary melanomas is a rare but well recognized disease, with an estimated incidence ranging from 1.75% to 8.5% in melanoma patients....

  • DIFICULTÄ‚Å¢I DE DIAGNOSTIC ÅžI TRATAMENT ÃŽNTR-UN CAZ DE MELANOM MALIGN. Petrescu, Marieta; Alexandru, Adrian; Benga, Andreea; Dumitrescu, Doina // Romanian Medical Journal;Sep2015, Vol. 62 Issue 3, p307 

    Malignant melanoma is a rare form of skin cancer, which is only about 3-4% of all skin cancers, but results in a mortality rate up to 65-70%. The vast majority of melanomas are diagnosed in stage 0, I and II, but there were cases when the primary diagnosis of malignant melanoma patients was put...

  • Melanoma staging guides treatment. McAvoy, Brian // New Zealand Doctor;4/8/2009, p16 

    The article discusses the clinical management of melanoma. After diagnosing melanoma, a patient will undergo further investigations to determine occult regional or systemic disease. Such investigations may include radiology, serum lactate dehydrogense and magnetic resonance imaging. Local...

  • Screening for Skin Cancer. Ferrini, Rebecca // American Family Physician;4/1/2002, Vol. 65 Issue 7, p1401 

    Presents a case study of a patient with melanoma. Incidence of melanoma; Clinical manifestation of the skin condition; Diagnostic approach for melanoma.

  • Current clinical overview of cutaneous melanoma. Lens, Marko // British Journal of Nursing;3/13/2008, Vol. 17 Issue 5, p300 

    This article reviews current evidence on epidemiology, diagnosis and management of cutaneous melanoma. Incidence of cutaneous melanoma is rising in all Caucasian populations across the world; thus, melanoma represents a significant public health burden. Although, incidence of melanoma is in...

  • Prognostický význam osteoprotegerinu a osteopontinu u maligního melanomu. Třešková, I.; Topolčan, O.; Vrzalova, J.; Pizinger, K. // Czecho-Slovak Dermatology / Cesko-Slovenska Dermatologie;2013, Vol. 88 Issue 6, p280 

    Aim: The aim of our study was to evaluate the dynamics of biomarkers osteoprotegerin and osteopontin and their relationship to prognosis of patients with malignant melanoma during the period from 2009 to 2012. Method: We evaluated a group of patients with malignant melanoma (n = 77) and control...

  • Key to melanoma -- look for change.  // New Zealand Doctor;6/2/2004, p29 

    Presents guidelines for general practitioners on the diagnosis and treatment of a type of skin cancer called melanoma in New Zealand. Incidence of melanoma; Focus of skin cancer prevention activities; Risks for melanoma; Subtypes of melanoma; Treatments and staging procedures for melanoma.

  • Genetic susceptibility in familial melanoma from northeastern Italy. Landi, M.T.; Golstein, A.M.; Ter-Minassian, M.; Tsang, S.; Munroe, D.; Modi, W.; Dean, M.; Metheny, N.; Steighner, R.; Staats, B.; Agatep, R.; Hogg, D.; Calista, D. // Journal of Medical Genetics;Jul2004, Vol. 41 Issue 7, p557 

    Discusses the genetic susceptibility in familial melanoma from northeastern Italy. Description of cutaneous malignant melanoma as a fatal form of skin cancer; Discussion of the cases of patients with primary melanomas, dysplastic nevi and pancreatic cancer; Link of harbour loci to melanoma.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics